- Home
- TOVX vs PCSA Comparison
TOVX vs PCSA Comparison
Compare TOVX & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- PCSA
- Stock Information
- Founded
- TOVX 2001
- PCSA 2011
- Country
- TOVX United States
- PCSA United States
- Employees
- TOVX N/A
- PCSA N/A
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- TOVX Health Care
- PCSA Health Care
- Exchange
- TOVX Nasdaq
- PCSA Nasdaq
- Market Cap
- TOVX 3.2M
- PCSA 3.1M
- IPO Year
- TOVX 2006
- PCSA N/A
- Fundamental
- Price
- TOVX $1.48
- PCSA $0.82
- Analyst Decision
- TOVX Strong Buy
- PCSA Strong Buy
- Analyst Count
- TOVX 1
- PCSA 2
- Target Price
- TOVX $6.00
- PCSA $5.00
- AVG Volume (30 Days)
- TOVX 1.2M
- PCSA 87.9K
- Earning Date
- TOVX 11-12-2024
- PCSA 10-30-2024
- Dividend Yield
- TOVX N/A
- PCSA N/A
- EPS Growth
- TOVX N/A
- PCSA N/A
- EPS
- TOVX N/A
- PCSA N/A
- Revenue
- TOVX N/A
- PCSA N/A
- Revenue This Year
- TOVX N/A
- PCSA N/A
- Revenue Next Year
- TOVX N/A
- PCSA N/A
- P/E Ratio
- TOVX N/A
- PCSA N/A
- Revenue Growth
- TOVX N/A
- PCSA N/A
- 52 Week Low
- TOVX $1.14
- PCSA $0.80
- 52 Week High
- TOVX $17.00
- PCSA $7.14
- Technical
- Relative Strength Index (RSI)
- TOVX 49.48
- PCSA 39.52
- Support Level
- TOVX $1.42
- PCSA $0.80
- Resistance Level
- TOVX $2.03
- PCSA $0.91
- Average True Range (ATR)
- TOVX 0.17
- PCSA 0.08
- MACD
- TOVX -0.01
- PCSA -0.00
- Stochastic Oscillator
- TOVX 12.70
- PCSA 7.82
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its "regulatory science" approach in the development of Next Generation Chemotherapy ("NGC") oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small molecule oncology drugs. The NGC products are new chemical entities, but the company work by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are - NGC-Capecitabine (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).